J&J to resume pivotal study of COVID-19 vaccine

• Johnson & Johnson (NYSE:JNJ) says it is preparing to resume a large clinical trial of its experimental COVID-19 vaccine after finding no evidence the vaccine caused an "unexplained illness" in a study volunteer that caused the company to pause the trial earlier this month.
• J&J says an independent data safety and monitoring board recommends resuming recruitment of study subjects for the trial, and it has consulted with U.S. regulators while taking steps to resume the trial.
• The company has not offered further details about the nature of the illness in the study subject.
• The J&J trial aims to enroll as many as 60K people in the U.S. and other countries to test whether a single dose safely protects people from COVID-19.
• https://seekingalpha.com/news/3625481-j-and-j-to-resume-pivotal-study-of-covidminus-19-vaccine